Wednesday, November 4th 2020
1:00-2:30 pm ET
Modeling Cancer in 3 Dimensions Using Patient-Derived 3D Cultures, presented by Pilar de la Puente, PhD
Lack of efficacy and a low overall success rate of phase I-II clinical trials are the most common failures when it comes to advancing cancer treatment. We have developed a patient-derived 3D culture model to overcome these limitations in breast cancer. Our patient-derived model is capable of supporting the growth and expansion of primary tumors recapitulating the tumor microenvironment constituents and modeling cancer treatment responses to predict clinically effective drug treatment concentrations.
Validating the Environmental Exposure Unit as an Experimental Clinical Model for Perennial Allergic Rhinitis, presented by Lubnaa Hossenbaccus
The Environmental Exposure Unit (EEU) is a controlled allergen exposure facility housed in the Kingston Health Sciences Centre in Kingston, Canada. It is one of a number of controlled allergen challenge facilities (CACFs) around the world used to study allergic rhinitis (AR). AR is an inflammatory disease of the nasal mucosa triggered by allergen exposure. While seasonal allergens such as ragweed have previously been investigated in the EEU, house dust mite, a perennial allergen, has yet to be studied.
For further information, please visit: www.pcrm.org/ERA21